Table 1 Demographic and clinical details of patients.

Number of patients included		811
Seizure type
Generalised seizures		130 (16%)
Focal seizures		517 (64%)
Mixed seizures		155 (19%)
Seizure type unknown		9 (1%)
Epilepsy syndrome
Cryptogenic focal epilepsy		238 (29%)
Symptomatic focal epilepsy		416 (51%)
Idiopathic generalised epilepsy		68 (8%)
Other epilepsy syndrome		68 (8%)
Not classifiable		21 (3%)
Age, years; mean (range)		37 (14 to 79)
Sex (Female/Male)		410/401
Age at seizure onset, years; mean (range)		11 (0 to 63)
With/without learning disability/not known		164/493/154
Maximum recorded daily dose, mg; mean (range)		2267 (62.5* to 5000)
Treatment time, months; mean (range)		16.7 (0 to 41)
Disposition:
Continuing at last follow‐up		528 (65%)
Stopped Lev
Adverse events only		81 (10%)
Inefficacy only		110 (14%)
Adverse events and inefficacy		75 (9%)
Pregnancy		3 (0.4%)
Deceased		7 (0.9%)
Unknown		7 (0.9%)
Concurrent AEDs at start
None		39 (5%)
One		253 (31%)
Two		330 (41%)
Three		151 (19%)
Four or more		36 (4%)
Unknown		2 (0.2%)

*Quarter of a 250 mg tablet. Units are number (%) unless otherwise stated.